CRS treatment consists of non-specific intensive care measures, such as intravenous fluids, vasopressors and occasionally ventilatory support, along with specific cytokine-blocking therapies, namely IL-6 (siltuximab), IL-6R (tocilizumab) or IL-1 (anakinra) blockers and corticosteroids [15,20,22]. Here, IL6R is linked to congenital rubella syndrome.